Addition of SRL 172 to standard chemotherapy in small cell lung cancer (SCLC) improves symptom control

Lung Cancer. 2005 Feb;47(2):289-90. doi: 10.1016/j.lungcan.2004.08.013.

Authors

C L Harper-Wynne, K Sumpter, C Ryan, K Priest, A Norton, P Ross, H E R Ford, P Johnson, M E R O'Brien

PMID: 15639729
DOI: 10.1016/j.lungcan.2004.08.013

No abstract available

Publication types

Clinical Trial
Letter
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bacterial Vaccines / administration & dosage
Bacterial Vaccines / adverse effects
Bacterial Vaccines / therapeutic use*
Carcinoma, Small Cell / drug therapy*
Humans
Lung Neoplasms / drug therapy*
Mycobacterium
Survival Analysis

Substances

Bacterial Vaccines
SRL172